DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 205873
NDA 205873 describes CISATRACURIUM BESYLATE, which is a drug marketed by Accord Hlthcare, Fresenius Kabi Usa, Hospira Inc, Jiangsu Hengrui Med, Sandoz Inc, and Somerset Theraps Llc, and is included in eleven NDAs. It is available from four suppliers. Additional details are available on the CISATRACURIUM BESYLATE profile page.
The generic ingredient in CISATRACURIUM BESYLATE is cisatracurium besylate. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.
The generic ingredient in CISATRACURIUM BESYLATE is cisatracurium besylate. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.
Summary for 205873
| Tradename: | CISATRACURIUM BESYLATE |
| Applicant: | Accord Hlthcare |
| Ingredient: | cisatracurium besylate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2MG BASE/ML | ||||
| Approval Date: | Jun 16, 2017 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
